{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2025-P-4282\" and posted_year = 2026 sorted by posted_date descending", "rows": [["FDA-2025-P-4282-0172", "FDA", "FDA-2025-P-4282", "Reference 27 - Large - Violence in first-episode psychosis A systematic review and meta-analysis", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:10Z", null, 0, 0, "09000064b91d3d7f"], ["FDA-2025-P-4282-0154", "FDA", "FDA-2025-P-4282", "Reference 9 - Chalasani - Clozapine Impact on Clinical Outcomes and Aggression in Severely Ill Adolescents with Childhood-Onset Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:18Z", null, 0, 0, "09000064b91d3d6d"], ["FDA-2025-P-4282-0160", "FDA", "FDA-2025-P-4282", "Reference 15 - di Giacomo et al - Prescribing Patterns of Psychotropic Drugs and Risk of Violent Behavior", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:36Z", null, 0, 0, "09000064b91d3d73"], ["FDA-2025-P-4282-0164", "FDA", "FDA-2025-P-4282", "Reference 19 - Fazel et al - Schizophrenia and Violence Systematic Review and Meta-Analysis", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:49Z", null, 0, 0, "09000064b91d3d77"], ["FDA-2025-P-4282-0167", "FDA", "FDA-2025-P-4282", "Reference 22 - Galletly - Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:57Z", null, 0, 0, "09000064b91d3d7a"], ["FDA-2025-P-4282-0148", "FDA", "FDA-2025-P-4282", "Reference 4 - Bitter - Effectiveness of Clozapine Olanzapine Quetiapine Risperidone and Haloperidol Monotherapy", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:42:58Z", null, 0, 0, "09000064b91d0f90"], ["FDA-2025-P-4282-0151", "FDA", "FDA-2025-P-4282", "Reference 7 - Cavaliere - Anti-Aggressive Effects of Clozapine in Involuntarily Committed Black Patients with Severe Mental Illness", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:09Z", null, 0, 0, "09000064b91d0f93"], ["FDA-2025-P-4282-0178", "FDA", "FDA-2025-P-4282", "Reference 33 - Sariaslan - Associations between individual antipsychotics and the Risk of Arrests and Convictions of Violent and Other Crime", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:30Z", null, 0, 0, "09000064b91d3d85"], ["FDA-2025-P-4282-0150", "FDA", "FDA-2025-P-4282", "Reference 6 - Buckley - Violence and Schizophrenia Clozapine as a Specific Antiaggressive Agent", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:05Z", null, 0, 0, "09000064b91d0f92"], ["FDA-2025-P-4282-0156", "FDA", "FDA-2025-P-4282", "Reference 11 - Citrome - Specific Anti-hostility Effects of Atypical Antipsychotics in Persons with Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:24Z", null, 0, 0, "09000064b91d3d6f"], ["FDA-2025-P-4282-0158", "FDA", "FDA-2025-P-4282", "Reference 13 - de Domenico - The effect of clozapine of aggressive behaviour in patients with chronic schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:30Z", null, 0, 0, "09000064b91d3d71"], ["FDA-2025-P-4282-0169", "FDA", "FDA-2025-P-4282", "Reference 24 - Herman - Clinical Response to Clozapine Treatment of 11 Chronic Patients in a State Psychiatric Hospital", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:02Z", null, 0, 0, "09000064b91d3d7c"], ["FDA-2025-P-4282-0155", "FDA", "FDA-2025-P-4282", "Reference 10 - Chiles - Effects of Clozapine on Use of Seclusion and Restraint at a State Hospital", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:21Z", null, 0, 0, "09000064b91d3d6e"], ["FDA-2025-P-4282-0159", "FDA", "FDA-2025-P-4282", "Reference 14 - Dennis - Clozapine Therapy in a State Hospital", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:33Z", null, 0, 0, "09000064b91d3d72"], ["FDA-2025-P-4282-0163", "FDA", "FDA-2025-P-4282", "Reference 18 - Fazel Grann - The Population Impact of Severe Mental Illness on Violent Crime", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:46Z", null, 0, 0, "09000064b91d3d76"], ["FDA-2025-P-4282-0168", "FDA", "FDA-2025-P-4282", "Reference 23 - Gammon - Clozapine Why Is It So Uniquely Effective in the Treatment ofa Range of Neuropsychiatric Disorders", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:00Z", null, 0, 0, "09000064b91d3d7b"], ["FDA-2025-P-4282-0182", "FDA", "FDA-2025-P-4282", "Reference 37 - Wagner et al - Clozapine Optimization A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:42Z", null, 0, 0, "09000064b91d3d89"], ["FDA-2025-P-4282-0152", "FDA", "FDA-2025-P-4282", "Reference 8 - Clozapine Impact on Clinical Outcomes and Aggression in Severly Ill Adolescents with Childhood-Onset Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:12Z", null, 0, 0, "09000064b91d3d6b"], ["FDA-2025-P-4282-0171", "FDA", "FDA-2025-P-4282", "Reference 26 - Kranzler - Clozapine Its Impact on Aggressive Behavior Among Children and Adolescents with Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:08Z", null, 0, 0, "09000064b91d3d7e"], ["FDA-2025-P-4282-0173", "FDA", "FDA-2025-P-4282", "Reference 28 - Newman - Management of Aggression", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:13Z", null, 0, 0, "09000064b91d3d80"], ["FDA-2025-P-4282-0175", "FDA", "FDA-2025-P-4282", "Reference 30 - Potkin - Predicting Suicidal Risk in Schizophrenic and Schizoaffective Patients in a Prospective Two-Year Trial", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:19Z", null, 0, 0, "09000064b91d3d82"], ["FDA-2025-P-4282-0179", "FDA", "FDA-2025-P-4282", "Reference 34 - Shaheen - The Effect of Clozapine on Violence - Aggression in Adults with Mental Illness and Personality Disorders", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:33Z", null, 0, 0, "09000064b91d3d86"], ["FDA-2025-P-4282-0181", "FDA", "FDA-2025-P-4282", "Reference 36 - Volavka - Efficacy of Clozapine Olanzapine Risperidone and Haloperidol in Schizophrenia and Schizoaffective Disorder", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:39Z", null, 0, 0, "09000064b91d3d88"], ["FDA-2025-P-4282-0146", "FDA", "FDA-2025-P-4282", "Reference 2 - Barnes - Evidence-based Guidelines for the Pharmacological Treatment of Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:42:51Z", null, 0, 0, "09000064b91d0f8e"], ["FDA-2025-P-4282-0176", "FDA", "FDA-2025-P-4282", "Reference 31 - Rabinowitz - Effect of clozapine on physical and verbal aggression", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:23Z", null, 0, 0, "09000064b91d3d83"], ["FDA-2025-P-4282-0166", "FDA", "FDA-2025-P-4282", "Reference 21 - Frogley - A systematic review of the evidence of clozapines anti-aggressive effects", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:54Z", null, 0, 0, "09000064b91d3d79"], ["FDA-2025-P-4282-0180", "FDA", "FDA-2025-P-4282", "Reference 35 - Volavka - Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:36Z", null, 0, 0, "09000064b91d3d87"], ["FDA-2025-P-4282-0177", "FDA", "FDA-2025-P-4282", "Reference 32 - Reid - Internet Archive Interlibrary Loan Fulfillment", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:27Z", null, 0, 0, "09000064b91d3d84"], ["FDA-2025-P-4282-0149", "FDA", "FDA-2025-P-4282", "Reference 5 - Buchanan - The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:01Z", null, 0, 0, "09000064b91d0f91"], ["FDA-2025-P-4282-0153", "FDA", "FDA-2025-P-4282", "Reference 8a - Chengappa - Clozapine Its impact on Aggressive Behavior Among Patients in a State Psychiatric Hospital", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:15Z", null, 0, 0, "09000064b91d3d6c"], ["FDA-2025-P-4282-0157", "FDA", "FDA-2025-P-4282", "Reference 12 - Citrome - Effects of Clozapine Olanzapine Risperidone and Haloperidol on Hostility Among Patients with Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:27Z", null, 0, 0, "09000064b91d3d70"], ["FDA-2025-P-4282-0161", "FDA", "FDA-2025-P-4282", "Reference 16 - Ebrahim - Patient Response to Clozapine in a Forensic Psychiatric Hospital", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:41Z", null, 0, 0, "09000064b91d3d74"], ["FDA-2025-P-4282-0165", "FDA", "FDA-2025-P-4282", "Reference 20 - Fazel et al - Violent crime suicide and premature mortality in patients with schizophrenia and related disorders", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:51Z", null, 0, 0, "09000064b91d3d78"], ["FDA-2025-P-4282-0170", "FDA", "FDA-2025-P-4282", "Reference 25 - Keepers - The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:05Z", null, 0, 0, "09000064b91d3d7d"], ["FDA-2025-P-4282-0174", "FDA", "FDA-2025-P-4282", "Reference 29 - Nolan - Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and Schizoaffective Disorder", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:44:16Z", null, 0, 0, "09000064b91d3d81"], ["FDA-2025-P-4282-0145", "FDA", "FDA-2025-P-4282", "Reference 1 - Balbuena - Does Clozapine Promote Employability and Reduce Offending Among Mentally Disordered Offenders", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:42:48Z", null, 0, 0, "09000064b91d0f8d"], ["FDA-2025-P-4282-0147", "FDA", "FDA-2025-P-4282", "Reference 3 - Bhavsar - Clozapine Treatment and Offending A Within-Subject Study of Patients With Psychotic Disorders in Sweden", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:42:54Z", null, 0, 0, "09000064b91d0f8f"], ["FDA-2025-P-4282-0162", "FDA", "FDA-2025-P-4282", "Reference 17 - Faden - A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder", "Supporting & Related Material", "Background Material", "2026-02-24T05:00:00Z", 2026, 2, null, null, "2026-02-25T02:43:43Z", null, 0, 0, "09000064b91d3d75"]], "truncated": false, "filtered_table_rows_count": 38, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 and \"posted_year\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA-2025-P-4282", "p1": "2026"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2025-P-4282&posted_year=2026", "results": [{"value": "FDA", "label": "FDA", "count": 38, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2025-P-4282&posted_year=2026&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2025-P-4282&posted_year=2026", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 38, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2025-P-4282&posted_year=2026&document_type=Supporting+%26+Related+Material", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2025-P-4282&posted_year=2026", "results": [{"value": 2026, "label": 2026, "count": 38, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2025-P-4282", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2025-P-4282&posted_year=2026&_facet_date=posted_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2025-P-4282&posted_year=2026&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 142.7574959816411, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}